A 58-year-old woman undergoes imaging for a 2-year history of progressive pain and swelling in the right submandibular region. CT shows a heterogeneous, infiltrative mass with bone erosion and skin involvement. Biopsy confirms mucoepidermoid carcinoma (high-grade). The tumor is deemed unresectable due to extensive soft tissue and bone invasion. What is the drug of choice for management?

Explanation

## Management of Advanced Malignant Salivary Gland Tumors ### Clinical Context The patient has a high-grade mucoepidermoid carcinoma (MEC) of the submandibular gland with: - Aggressive features: pain, infiltration, bone erosion, skin involvement - Unresectable disease: extensive local invasion - High-grade histology: poor prognosis, high metastatic potential ### Treatment Strategy for Unresectable Disease **Key Point:** Concurrent chemoradiotherapy (CCRT) is the standard of care for unresectable, high-grade salivary gland malignancies. ### Cisplatin-Based CCRT: Rationale | Feature | Rationale | |---------|----------| | **Chemotherapy agent** | Cisplatin is the most active agent in salivary gland cancers; synergizes with radiotherapy | | **Concurrent delivery** | Radiosensitization: cisplatin enhances tumor cell death from radiation | | **Radiotherapy dose** | 60–70 Gy to primary and involved nodes | | **Timing** | Cisplatin given weekly (40 mg/m²) or every 3 weeks (100 mg/m²) during RT | | **Goal** | Locoregional control in unresectable disease; potential for cure in select cases | **High-Yield:** Cisplatin is the backbone of systemic therapy for salivary gland malignancies because of superior outcomes in phase II/III trials compared to other agents. ### Why Other Options Fail **Clinical Pearl:** Monotherapy (cetuximab, erlotinib, paclitaxel alone) is insufficient for high-grade, unresectable disease. These are used: - **Cetuximab:** Adjuvant or palliative in recurrent/metastatic disease; not first-line for primary unresectable tumors. - **Erlotinib:** Targeted therapy for EGFR-mutant tumors; not standard first-line and lacks robust evidence in salivary gland cancers. - **Paclitaxel:** Palliative agent for metastatic disease; insufficient as monotherapy for unresectable primary tumors. ### Treatment Pathway ```mermaid flowchart TD A[High-grade salivary gland malignancy]:::outcome --> B{Resectable?}:::decision B -->|Yes| C[Surgery ± adjuvant RT/CCRT]:::action B -->|No| D[Unresectable]:::urgent D --> E{Metastatic?}:::decision E -->|No| F[Concurrent cisplatin + RT]:::action E -->|Yes| G[Palliative chemotherapy<br/>or targeted therapy]:::action F --> H[Locoregional control]:::outcome G --> I[Symptom palliation]:::outcome ``` **Warning:** Do not confuse unresectable primary disease (requires CCRT) with metastatic disease (requires palliative chemotherapy ± immunotherapy). This patient has unresectable local disease, not distant metastases. [cite:Harrison 21e Ch 29; NCCN Head and Neck Cancer Guidelines 2023]